<DOC>
	<DOCNO>NCT00779636</DOCNO>
	<brief_summary>This placebo control study design evaluate effectiveness desloratadine relieve symptom allergic airway disease pollen season . Patients receive desloratadine 10 mg placebo daily 28 day , allergy symptom side effect medication measure Day 1 , Day 15 , Day 29 ( one day stop study drug ) .</brief_summary>
	<brief_title>Effectiveness Safety Desloratadine Patients With Allergic Airway Disease During Pollen Season ( Study P03284 )</brief_title>
	<detailed_description />
	<mesh_term>Desloratadine</mesh_term>
	<mesh_term>Loratadine</mesh_term>
	<criteria>18 65 year old least twoyear history seasonal allergic rhinitis presence chest symptom ( cough , wheeze , difficulty breathe ) associate allergy season FEV1 great equal 70 % predict skin test positive ( skin prick test ) Total Nasal Symptom Severity Score &gt; = 6 Screening Visit . Total Chest Symptom Severity Score &gt; = 3 Screening Visit . Total Frequency Chest Symptoms and/or Total Frequency Bronchodilator Use least 2 Screening Visit Total Nasal Symptom Severity Score &gt; = 6 7 15 runin diary timepoints . Total Chest Symptom Severity Score &gt; = 3 7 15 runin diary timepoints Free clinically significant disease would interfere study evaluation . Subjects : demonstrate change FEV1 &gt; = 20 % Visit 2 Visit 3. use &gt; 12 puff ProventilÂ® HFA ( beta2agonist ) 2 consecutive day treatment nebulized beta2 agonist screen period Visit 2 Visit 3. require chronic use inhale systemic corticosteroid . require regular treatment nebulized beta2agonists . require short act beta2 agonist use every exercise session exposure animal . current history frequent ( 2 episode per year past 2 year ) , clinically significant sinusitis chronic purulent postnasal drip . rhinitis medicamentosa chronic obstructive pulmonary disease ( COPD ) . upper low respiratory tract sinus infection require antibiotic therapy last dose 14 day prior Screening , upper low viral respiratory infection within 7 day prior Screening . nasal structural abnormality , include large nasal polyp mark septal deviation significantly interfere nasal air flow . opinion Investigator , dependent upon nasal , oral ocular decongestant , nasal topical antihistamine , nasal steroid . immunotherapy ( desensitization therapy ) , unless regular maintenance schedule prior Screening visit stay schedule remainder study . Subjects could receive desensitization treatment within 24 hour prior study visit . smoke , exsmokers smoke within previous six month . current evidence clinically significant hematopoietic , cardiovascular , hepatic , immunologic , renal , neurologic , psychiatric , autoimmune disease , disease precludes subject 's participation study subject 's ability complete diary card . morbidly obese ( BMI &gt; = 35 ) . nightshift worker standard asleep night / awake day cycle . history life threaten asthma attack subject treat emergency room admit hospital asthma control within previous 3 month previous 6 month .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>